Adding Tafasitamab to Lenalidomide and Rituximab Prolongs PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 18, 2025 324 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR FDA Grants Accelerated Approval to Tepotinib for Metastatic NSCLC February 5, 2021 FDA Grants Accelerated Approval to Tisotumab Vedotin-tftv for Recurrent or Metastatic... September 23, 2021 FDA Approves Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma April 27, 2022 ΙΣΤΟΡΙΑ January 18, 2019 Load more HOT NEWS Pirtobrutinib Shows Efficacy in Patients with Heavily Pretreated CLL or SLL... “Oncometabolite” Neutralizes Immune Cells Near Tumors Teen Helps Mom With Cancer Shave Her Head, Then Turns To... Empoderar a las personas con cáncer: preguntas y respuestas con la...
